Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry)
Toru Naganuma(New Tokyo Hospital), Sunao Nakamura(New Tokyo Hospital), Hisao Ogawa(Kumamoto University Hospital), Kenichi Tsujita(Kumamoto University), Kenji Sakamoto(Kumamoto University), Satoru Mitomo(New Tokyo Hospital), Suguru Nagamatsu(Kumamoto University), Jun–ei Obata(University of Yamanashi), Katsumasa Sato(Fukuyama Cardiovascular Hospital), Sandeep Basavarajaiah(Heart of England NHS Foundation Trust), Eiichiro Yamamoto(Sapporo Medical University), Sunao Kojima(Kumamoto University), Tsuyoshi Kobayashi(University of Yamanashi), Koichi Kaikita(Kumamoto University), Yasuhiro Izumiya(Kumamoto University), Naohiro Komura(Kumamoto University), Hisaaki Ishiguro(New Tokyo Hospital), Kenshi Yamanaga(Kumamoto University)
Cited by 13
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755